Cognitive Effectiveness of Somatotherapy and Occupational Therapy in Post-Stroke Patients. (CESTO)

June 4, 2026 updated by: Muslim khan, Iqra National University

The Cognitive Effectiveness of Somatotherapy & Occupational Therapy in Post-Stroke Patients

The objective of this study was to evaluate the cognitive effectiveness of somatotherapy and occupational therapy in post-stroke patients by measuring their cognitive potential outcomes using the Montreal Cognitive Assessment (MoCA) test.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Stroke is a leading cause of death and long-term disability worldwide. Cognitive impairment is a common and disabling consequence of stroke that significantly affects patients' functional independence and quality of life.

Somatotherapy (targeted physical and sensorimotor therapy) and occupational therapy (focused on activities of daily living) are frequently used rehabilitation approaches, but their combined effect on cognitive recovery in post-stroke patients requires further evaluation.

This was a single-center, retrospective observational study conducted at the department of physical therapy, King Hospital, Swat, Pakistan. Medical records of 50 post-stroke patients (30 males, 20 females; age range 30-60 years) who received inpatient rehabilitation between 2018 and 2019 were analyzed.

Participants

Study Type

Observational

Enrollment (Actual)

50

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Pakistan
    • Khyber Pakhtunkhwa
      • Swat, Khyber Pakhtunkhwa, Pakistan, 26000
        • Swat Medical Complex

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

50 post-stroke patients (30 males and 20 females) who were referred to the Department of Physical Therapy at King Hospital, Swat, Pakistan between 2018 and 2019 for cognitive rehabilitation.

Participants were adult stroke patients (approximate mean age around 60 years) with either ischemic or hemorrhagic stroke who received 4 weeks of inpatient combined somatotherapy and occupational therapy.

Description

Inclusion Criteria

  • Adults aged 30 years and above
  • Diagnosed with ischemic or hemorrhagic stroke (first-ever or recurrent)
  • Referred to physical therapy department for cognitive rehabilitation
  • Received somatotherapy and occupational therapy during hospitalization
  • Able to undergo MoCA (Montreal Cognitive Assessment) testing

Exclusion Criteria:

  • Severe speech impairment (aphasia) that prevents reliable cognitive testing
  • Significant visual impairment that interferes with MoCA testing
  • Significant hearing impairment that interferes with MoCA testing
  • Inability to participate in therapy sessions.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Montreal Cognitive Assessment
Time Frame: 4 weeks
To detect mild cognitive impairment and assess for early stages of dementia. This scale utilizes a minimum value of 0 and a maximum value of 30, where higher scores mean a better outcome (a score of 26 or above is considered normal, while a score of 22 suggests mild cognitive impairment.
4 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Iqra National University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 3, 2023

Primary Completion (Actual)

December 25, 2025

Study Completion (Actual)

December 25, 2025

Study Registration Dates

First Submitted

May 8, 2026

First Submitted That Met QC Criteria

June 4, 2026

First Posted (Actual)

June 9, 2026

Study Record Updates

Last Update Posted (Actual)

June 9, 2026

Last Update Submitted That Met QC Criteria

June 4, 2026

Last Verified

June 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IQRA-00023
  • Iqra-023 (Registry Identifier: Clinical Trial)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

ndividual participant data will not be shared publicly. The study is a small retrospective analysis based on hospital medical records. Sharing IPD is not planned due to:

Ethical and privacy concerns (patient confidentiality and data protection regulations).

The retrospective nature of the study with no prior consent obtained from participants for data sharing.

Local institutional policies at King Hospital regarding data sharing.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Cognitive Impairment

Clinical Trials on Somatotherapy and Occupational Therapy

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Chile

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe